Key takeaways
- Anastrozole blocks the enzyme that converts testosterone to estradiol.
- In men, estradiol is not a contaminant — it is the dominant regulator of bone resorption and contributes to libido, mood and vascular function, so lowering it has a cost.
- Anastrozole inhibits aromatase, the enzyme that converts testosterone to estradiol.
- Most of the harm here follows from a single false premise: that estradiol is a female hormone which men accumulate as a side effect and should minimise.
- The first is cultural inheritance: an older generation of testosterone practice treated estradiol as an enemy and lower as always better, and that assumption outlived the evidence.
Anastrozole solves a real problem for a small number of men on testosterone therapy. It is prescribed to a far larger number, usually before anyone has established that the problem exists. The result is a predictable pattern: men who arrive with symptoms they attribute to testosterone therapy, whose symptoms are actually caused by the drug added alongside it. This is not a marginal error. Crushed estradiol is one of the most common iatrogenic problems in male hormone optimisation.
What the drug does
Anastrozole inhibits aromatase, the enzyme that converts testosterone to estradiol. Aromatase is expressed in fat tissue, bone, brain, liver and the testes themselves, so this is not a peripheral side-reaction being tidied up — it is a normal, continuous, necessary conversion happening throughout the body (the aromatase enzyme in detail).
On testosterone therapy the substrate goes up, so the product goes up with it. More testosterone means more raw material for aromatisation, and in some men estradiol rises above the range where they feel well. Anastrozole blunts that conversion and brings estradiol down (Burnett-Bowie et al., J Clin Endocrinol Metab 2009).
The critical framing is that the drug does not lower estradiol to a target. It lowers estradiol. Where it lands depends on the man's aromatase activity, his body fat, his dose and his individual sensitivity — which is why this is a medication that has to be measured rather than assumed.
Why estradiol in men is not a nuisance hormone
Most of the harm here follows from a single false premise: that estradiol is a female hormone which men accumulate as a side effect and should minimise. It is not. In men, estradiol is the dominant regulator of bone resorption, contributes to libido and erectile function, supports lipid handling and vascular function, and acts on mood and cognition.
The cleanest demonstration comes from an experiment designed to separate the two hormones, which ordinary observation cannot do because one is continuously being converted into the other. Suppress the axis, add back testosterone at varying doses, and block aromatisation in half the men. Body composition and sexual function tracked estradiol, not testosterone alone — blocking the conversion removed benefits even while testosterone itself was maintained (Finkelstein et al., NEJM 2013).
The bone consequence deserves particular emphasis, because it is silent. A man can feel adequate on suppressed estradiol for years while losing bone the whole time — see testosterone and bone density and the protective role of estradiol in men.
Why it gets prescribed anyway
Three forces keep the reflex alive. The first is cultural inheritance: an older generation of testosterone practice treated estradiol as an enemy and lower as always better, and that assumption outlived the evidence. The second is that it is easier to co-prescribe than to test, retest and interpret. The third is measurement error, which is the one that does the most damage.
Standard estradiol immunoassays were designed for the concentrations seen in women. At the much lower concentrations found in men they lose accuracy, and the direction of that error is not consistent — a man can be told his estradiol is high on the basis of a number that would not survive a better assay. Mass spectrometry is the reference method at these concentrations, and it is the one that should decide a prescribing question in men (sex steroid measurement by mass spectrometry in hypogonadal men, Andrology 2026).
A prescription written on an unreliable number, before any symptom exists, is the modal case of anastrozole misuse.
When it is appropriate
The threshold is a conjunction, not a single trigger. All of the following should hold:
- Sensitive estradiol confirmed elevated — above roughly 45 pg/mL on an LC-MS/MS assay, and confirmed on a repeat draw rather than acted on from one result
- With symptoms that fit — water retention, nipple or breast tenderness, mood lability, developing gynaecomastia
- After the upstream drivers have been addressed and the picture has not resolved
- In a confirmed high aromatiser, meaning the pattern persists at a reasonable testosterone dose
Dose, when it is used at all, is small and set by the prescriber — far smaller than the amounts used in the oncology setting the drug came from — and it is titrated against a repeat sensitive estradiol several weeks later. The measurement is not optional. Adjusting on assumed effect is how men end up crashed.
When it is not
- Prophylactically, alongside a first testosterone prescription, before any testing
- On the basis of a standard immunoassay alone
- For an estradiol in the 30-40 range in a man with no symptoms
- For a single elevated result that has never been repeated
- Where the testosterone dose is supraphysiologic and has not been reduced
- In a man already showing signs of low estradiol — joint pain, flat libido, low mood
The last one matters most, because those symptoms overlap almost perfectly with low testosterone symptoms. A man who feels worse on therapy is frequently assumed to need more intervention when what he needs is one drug removed. Low estrogen symptoms in men covers how to tell the two apart.
| High estradiol | Crashed estradiol | |
|---|---|---|
| Body | Puffiness, water retention, weight up quickly | Joints ache, dry, feels "brittle" |
| Breast tissue | Tenderness, sensitivity | No change |
| Libido | Variable, often preserved | Flat, and erections poorer despite good testosterone |
| Mood | Labile, emotional | Blunted, low, anhedonic |
| Silent risk | Gynaecomastia | Bone loss |
Address the upstream first
Elevated estradiol on therapy usually has a cause, and the cause is usually more tractable than it looks:
- Testosterone dose. If total testosterone is supraphysiologic, the substrate is the problem. Reducing the dose lowers estradiol without adding a drug — and often improves how the man feels for other reasons too.
- Injection frequency. Large, infrequent doses produce peaks; peaks produce aromatisation. More frequent, smaller administration flattens the curve.
- Visceral fat. Adipose tissue is where much of the aromatase lives, so body fat and estradiol move together. This is the slowest lever and the most durable one (testosterone and visceral fat).
- Alcohol. It impairs hepatic clearance of estrogens, so intake shows up directly in the number.
- Sleep. Poor sleep worsens insulin sensitivity and body composition, which feeds back into the first three.
A meaningful proportion of "high estradiol" resolves on these alone. Estradiol management on TRT sets out the order in which to work through them.
The clinical pearl: the reflex that every man on testosterone needs an aromatase inhibitor has harmed more men than it has helped. Treat estradiol as a hormone with a target range, not a contaminant to be minimised. Confirm elevation with a sensitive assay, require symptoms, address the dose and the body fat first, and if you do prescribe, retest — because the failure mode is silent and slow.
Bottom line
Anastrozole is a legitimate tool for a specific, confirmable situation: sensitive estradiol genuinely elevated, symptoms that match, upstream drivers already addressed, and follow-up testing to prove where it landed. Outside that situation it converts a man with a hormone problem into a man with two. Modern practice reserves it accordingly (Bhasin et al., J Clin Endocrinol Metab 2018). If you are on therapy and were given an aromatase inhibitor without a sensitive estradiol result and a symptom, that is worth raising with your physician — the 60-second assessment is a reasonable place to start the conversation.
Educational content, not medical advice. Laboratory interpretation and any treatment decision are made by a licensed physician after individual evaluation. Individual results vary.
